Can EPO reduce blood transfusion requirements during induction therapy for high-risk neuroblastoma?
Cazzola
Mario
M
Department of Hematology, University of Pavia, Italy. mario.cazzola@unipv.it
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001803:Blood Transfusion; D002986:Clinical Trials as Topic; D018572:Disease-Free Survival; D004921:Erythropoietin / Q000008:administration & dosage*; D006801:Humans; D009447:Neuroblastoma / Q000188:drug therapy* / Q000556:secondary; D015996:Survival Rate
D004921:Erythropoietin